Homeland Uranium Inc.

Homeland Uranium Inc.

June 16, 2009 11:34 ET

Homeland Uranium Inc. Provides Warrant Extension and Pricing Amendment

TORONTO, ONTARIO--(Marketwire - June 16, 2009) - Homeland Uranium Inc., ("Homeland" or the "Company") has announced that it has provided an exercise extension of its outstanding warrants for a total of 14,217,050 share purchase warrants issued in 2007, to now expire on June 19, 2010. All of the warrants were set to expire between June and August 2009.

The share purchase warrants exercise price has been amended from $1.25 to $0.80 per warrant.

As insiders of the Company hold 22% of the warrants, this extension and amendment has been approved by the independent directors of the Company.

"With several initiatives being undertaken by management to build the company, we feel that it is only fair that our shareholders have the opportunity to fully share in our growth," said Nick Tintor, President and CEO.


The Company is a natural resource company engaged in the acquisition, exploration and development of uranium properties. The Company's focus is on exploration for uranium in the Arlit region of Niger, where the Company has an interest in the Agelal Project and the Asekra Project, which include eight exploration concessions covering an area of approximately 3,731 square kilometers. The Company also holds rights to 10 exploration properties in Colorado and Utah, United States. Homeland owns approximately 23.9% of the issued and outstanding common shares of Macusani Yellowcake (TSX VENTURE:YEL) on a non-diluted basis. Macusani Yellowcake is developing an advanced stage uranium project in Macusani Plateau region of Peru.

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Contact Information